Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD

Abstract

There was no consensus on the optimal use of G-CSF after hematopoietic stem cell transplantation. In this study, the practice of using G-CSF, based on the CD34⁺ cell number, at the University of California, San Diego Blood and Marrow Transplant Unit (UCSD BMT) was evaluated by performing a five-year retrospective analysis of data from patients undergoing autologous and allogeneic transplantation. Various outcomes, such as time to neutrophil and platelet engraftment and length of post-transplant hospital stay are assessed in relation to use of G-CSF and number of CD34⁺ cells infused. It has been found that the use of G-CSF is associated with faster neutrophil engraftment and shorter length of post-transplant hospital stay without affecting time to platelet engraftment in patients undergoing autologous transplantation. In addition, the number of CD34⁺ cells do not influence outcomes in autologous and allogeneic transplant patients if they are treated with G-CSF. As a result of this evaluation, the G-CSF protocol at UCSD BMT Unit is revised. The main change is to implement the use of G-CSF in all patients undergoing autologous transplantation regardless of the number of CD34⁺ cells. No changes in the allogeneic transplantation protocol are made as a result of this analysis.

Keywords

G-CSF filgrastim autologous transplantation allogeneic transplantation peripheral blood stem cell transplantation hematopoietic stem cell transplantation

Get full access to this article

View all access options for this article.

References

Anderlini P. , Champlin R. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs 2002; 62 Suppl1: 79-88.

Bishop MR , Tarantolo SR , Geller RB , Lynch JC , Bierman PJ , Pavletic ZS , Vose JM , Kruse S. , Dix SP , Morris ME , Armitage JO , Kessinger A. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation . Blood 2000; 96: 80-85.

Klumpp TR , Mangan KF , Goldberg SL , Pearlman ES , Macdonald JS Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial . J Clin Oncol 1995; 13: 1323-27.

McQuaker IG , Hunter AE , Pacey S. , Haynes AP , Iqbal A. , Russell NH Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-57.

Richard S. , Schuster MW Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep 2002; 1: 103-09.

Smith LA , Wright-Kanuth MS Complications and risks in hematopoietic stem cell transplant patients. Clin Lab Sci 2001; 14: 118-24.

Smith TJ , Khatcheressian J. , Lyman GH , Ozer H. , Armitage JO , Balducci L. , Bennett CL , Cantor SB , Crawford J. , Cross SJ , Demetri G. , Desch CE , Pizzo PA , Schiffer CA , Schwartzberg L. , Somerfield MR , Somlo G. , Wade JC , Wade JL , Winn RJ , Wozniak AJ , Wolff AC 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205.

Trivedi M. , Martinez S. , Corringham S. , Medley K. , Ball ED Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transpl 2009; 43: 895-908.

Faucher C. , Le Corroller AG , Chabannon C. , Novakovitch G. , Manonni P. , Moatti JP , Nouyrigat P. , Maraninchi D. , Blaise D. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transpl 1996; 17: 533-36.

10.

Piccirillo N. , Sica S. , Laurenti L. , Chiusolo P. , La Barbera EO , Sorà F. , Leone G. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transpl 1999; 23: 1245-50.

11.

Valteau-Couanet D. , Faucher C. , Auperin A. , Michon J. , Milpied N. , Boiron JM , Bourhis JH , Gisselbrecht C. , Vernant JP , Pinna A. , Bendahmane B. , Delabarre F. , Benhamou E. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transpl 2005; 36: 547-52.

12.

Przepiorka D. , Smith TL , Folloder J. , Anderlini P. , Chan KW , Körbling M. , Lichtiger B. , Norfleet F. , Champlin R. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97: 3405-410.

13.

Stinson TJ , Adams JR , Bishop MR , Kruse S. , Tarantolo S. , Bennet CL Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transpl 2000; 26: 663-66.

14.

Ciernik IF , Schanz U. , Gmur J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transpl 1999 ; 24: 147-51.

15.

Hagglund H. , Ringden O. , Oman S. , Remberger M. , Carlens S. , Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transpl 1999; 24: 831-36.

16.

Himmelmann B. , Himmelmann A. , Furrer K. , Halter J. , Schanz U. Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial . Bone Marrow Transpl 2002; 30: 491-96.

17.

Lee KH , Lee JH , Choi SJ , Kim S. , Lee JS , Kim S. H, Kim WK Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transpl 1999; 24: 591-99.